Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PhotoCure ASAFRA:PHS +0.19%71 3-1 Month Momentum % is -7.33% as of Jul. 15, 2026. GuruFocus rates FRA:PHS with a GF Score™ of 71/100 and a GF Value™ of €6.29 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 1,023 Drug Manufacturers companies, PhotoCure ASA ranks worse than 62.85% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-15), PhotoCure ASA's 3-1 Month Momentum % is -7.33%.
The industry rank for PhotoCure ASA's 3-1 Month Momentum % or its related term are showing as below:
FRA:PHS's 3-1 Month Momentum % is ranked worse than 62.85% of 1023
companies
in the Drug Manufacturers industry
Industry Median: -8.02
vs FRA:PHS: -7.33
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
PhotoCure ASA 3-1 Month Momentum % Related Terms
FRA:PHS vs ZTS, UTHR, VTRS: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PhotoCure ASA's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PhotoCure ASA 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PhotoCure ASA's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where PhotoCure ASA's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PhotoCure ASA (FRA:PHS) has a 3-1 Month Momentum % of -7.33% as of Jul. 15, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on PhotoCure ASA and its competitors. According to the industry distribution chart, PhotoCure ASA ranks #643 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 62.9%.
Is PhotoCure ASA's 3-1 Month Momentum % too high?
PhotoCure ASA's current 3-1 Month Momentum % is -7.33%. Based on the distribution chart, PhotoCure ASA ranks #643 out of 1023 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, PhotoCure ASA has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PhotoCure ASA's 3-1 Month Momentum % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PhotoCure ASA ranks #643 out of 1023 companies for 3-1 Month Momentum %. This places PhotoCure ASA in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
A good 3-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on PhotoCure ASA and its competitors. PhotoCure ASA's current 3-1 Month Momentum % is -7.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhotoCure ASA stock overvalued right now?
Based on GuruFocus' analysis, PhotoCure ASA (FRA:PHS) is currently considered Modestly Undervalued. The stock's GF Value™ is €6.29, compared to a current price of €5.21 — trading 17.2% below its estimated fair value. The current 3-1 Month Momentum % is -7.33%. PhotoCure ASA's overall GF Score™ is 71/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For PhotoCure ASA (FRA:PHS), the current 3-1 Month Momentum % is -7.33% as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PhotoCure ASA (FRA:PHS) Overvalued in 2026?
Based on GuruFocus' analysis, PhotoCure ASA stock appears to be undervalued.
The current stock price of €5.21 is trading 17.2% below its estimated GF Value™ of €6.29.
GuruFocus considers PhotoCure ASA to be Modestly Undervalued.
Key valuation signals for FRA:PHS:
3-1 Month Momentum %: -7.33%
GF Value™: €6.29 vs. price of €5.21 (17.2% below fair value)
No single metric tells the full story. See the FRA:PHS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PhotoCure ASA is a Norway-based business group associated with the research, development, production, distribution, marketing, and sales of pharmaceutical products and specialty pharmaceutical companies. The technology platform of the company is focused on the field of photodynamic diagnosis and treatment of cancer. The company has two operating segments of the group the Commercial franchise and the Development portfolio. It generates prime revenue from the Commercial franchise segment, which includes Hexvix and Cysview products. Its geographical segments are Nordic countries, Germany, France, Austria, the United Kingdom, BeNeLux, Italy, Other European countries, Canada, and the United States.
71GF Score
Get the complete analysis for FRA:PHS
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PHS has been successfully added to your 
